Literature DB >> 23015722

Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge.

Gayathri Bommakanti1, Xianghan Lu, Michael P Citron, Tariq Ahmad Najar, Gwendolyn J Heidecker, Jan ter Meulen, Raghavan Varadarajan, Xiaoping Liang.   

Abstract

The hemagglutinin protein (HA) on the surface of influenza virus is essential for viral entry into the host cells. The HA1 subunit of HA is also the primary target for neutralizing antibodies. The HA2 subunit is less exposed on the virion surface and more conserved than HA1. We have previously designed an HA2-based immunogen derived from the sequence of the H3N2 A/HK/68 virus. In the present study, we report the design of an HA2-based immunogen from the H1N1 subtype (PR/8/34). This immunogen (H1HA0HA6) and its circular permutant (H1HA6) were well folded and provided complete protection against homologous viral challenge. Antisera of immunized mice showed cross-reactivity with HA proteins of different strains and subtypes. Although no neutralization was observable in a conventional neutralization assay, sera of immunized guinea pigs competed with a broadly neutralizing antibody, CR6261, for binding to recombinant Viet/04 HA protein, suggesting that CR6261-like antibodies were elicited by the immunogens. Stem domain immunogens from a seasonal H1N1 strain (A/NC/20/99) and a recent pandemic strain (A/Cal/07/09) provided cross-protection against A/PR/8/34 viral challenge. HA2-containing stem domain immunogens therefore have the potential to provide subtype-specific protection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015722      PMCID: PMC3503045          DOI: 10.1128/JVI.01429-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  The role of the antibody response in influenza virus infection.

Authors:  W Gerhard
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes.

Authors:  R J Russell; S J Gamblin; L F Haire; D J Stevens; B Xiao; Y Ha; J J Skehel
Journal:  Virology       Date:  2004-08-01       Impact factor: 3.616

3.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

4.  The influenza virus resource at the National Center for Biotechnology Information.

Authors:  Yiming Bao; Pavel Bolotov; Dmitry Dernovoy; Boris Kiryutin; Leonid Zaslavsky; Tatiana Tatusova; Jim Ostell; David Lipman
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

5.  Helix propensities are identical in proteins and peptides.

Authors:  J K Myers; C N Pace; J M Scholtz
Journal:  Biochemistry       Date:  1997-09-09       Impact factor: 3.162

6.  Characterization of a novel influenza hemagglutinin, H15: criteria for determination of influenza A subtypes.

Authors:  C Röhm; N Zhou; J Süss; J Mackenzie; R G Webster
Journal:  Virology       Date:  1996-03-15       Impact factor: 3.616

7.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

8.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

9.  Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus.

Authors:  James Stevens; Adam L Corper; Christopher F Basler; Jeffery K Taubenberger; Peter Palese; Ian A Wilson
Journal:  Science       Date:  2004-02-05       Impact factor: 47.728

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  44 in total

1.  Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.

Authors:  Seth J Zost; Nicholas C Wu; Scott E Hensley; Ian A Wilson
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 2.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 4.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 5.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

Authors:  James E Crowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

Review 6.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

7.  Design and Structure of an Engineered Disulfide-Stabilized Influenza Virus Hemagglutinin Trimer.

Authors:  Peter S Lee; Xueyong Zhu; Wenli Yu; Ian A Wilson
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

8.  Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection.

Authors:  Vamsee V A Mallajosyula; Michael Citron; Francesca Ferrara; Xianghan Lu; Cheryl Callahan; Gwendolyn J Heidecker; Siddhartha P Sarma; Jessica A Flynn; Nigel J Temperton; Xiaoping Liang; Raghavan Varadarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

9.  Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.

Authors:  Sannula Kesavardhana; Raghavan Varadarajan
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 10.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.